Neurona Therapeutics Awarded $8 Million by California Institute for Regenerative Medicine (CIRM) to Support Phase I/II Clinical Trial of NRTX-1001 for Chronic Focal Epilepsy

Neurona Therapeutics announced that it has been awarded a $7,999,999 grant by the California Institute for Regenerative Medicine to support a dose-escalation Phase I/II clinical trial of NRTX-1001, an inhibitory cell therapy that is being evaluated for safety and efficacy in people with drug-resistant mesial temporal lobe epilepsy.